Concepts (167)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatic Neoplasms | 10 | 2022 | 45 | 3.110 |
Why?
|
| Prostatectomy | 4 | 2020 | 7 | 1.430 |
Why?
|
| Carcinoma, Renal Cell | 6 | 2024 | 10 | 0.970 |
Why?
|
| Kidney Neoplasms | 6 | 2024 | 12 | 0.960 |
Why?
|
| Male | 24 | 2022 | 3671 | 0.790 |
Why?
|
| Humans | 31 | 2024 | 6794 | 0.690 |
Why?
|
| Aged | 16 | 2020 | 1539 | 0.670 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2018 | 64 | 0.640 |
Why?
|
| Margins of Excision | 1 | 2019 | 1 | 0.620 |
Why?
|
| Prostate | 3 | 2022 | 15 | 0.600 |
Why?
|
| Middle Aged | 13 | 2020 | 2108 | 0.560 |
Why?
|
| Carcinoma, Transitional Cell | 4 | 2018 | 4 | 0.560 |
Why?
|
| Seminal Vesicles | 1 | 2016 | 1 | 0.510 |
Why?
|
| Microbiological Techniques | 1 | 2016 | 1 | 0.510 |
Why?
|
| Ureterostomy | 1 | 2016 | 1 | 0.510 |
Why?
|
| Urinalysis | 1 | 2016 | 5 | 0.500 |
Why?
|
| Catheter-Related Infections | 1 | 2016 | 4 | 0.500 |
Why?
|
| Urinary Tract Infections | 1 | 2016 | 9 | 0.500 |
Why?
|
| Stents | 1 | 2016 | 13 | 0.500 |
Why?
|
| Predictive Value of Tests | 4 | 2020 | 127 | 0.440 |
Why?
|
| Cystectomy | 3 | 2018 | 3 | 0.420 |
Why?
|
| Urinary Bladder Neoplasms | 3 | 2018 | 6 | 0.410 |
Why?
|
| Nephrectomy | 4 | 2020 | 14 | 0.370 |
Why?
|
| Female | 17 | 2019 | 4060 | 0.350 |
Why?
|
| Gastroesophageal Reflux | 1 | 2011 | 3 | 0.350 |
Why?
|
| Vesico-Ureteral Reflux | 1 | 2011 | 2 | 0.350 |
Why?
|
| Retrospective Studies | 6 | 2020 | 681 | 0.340 |
Why?
|
| United States | 4 | 2019 | 1019 | 0.320 |
Why?
|
| Finger Phalanges | 1 | 2008 | 1 | 0.290 |
Why?
|
| Adult | 7 | 2020 | 2113 | 0.260 |
Why?
|
| Tumor Burden | 3 | 2020 | 19 | 0.240 |
Why?
|
| Adipose Tissue | 2 | 2018 | 69 | 0.220 |
Why?
|
| Neoplasm Grading | 3 | 2022 | 10 | 0.210 |
Why?
|
| Aged, 80 and over | 3 | 2020 | 497 | 0.210 |
Why?
|
| Postoperative Complications | 4 | 2018 | 109 | 0.210 |
Why?
|
| Neoplasm Staging | 3 | 2020 | 45 | 0.200 |
Why?
|
| Antineoplastic Agents | 3 | 2018 | 72 | 0.200 |
Why?
|
| Patient Selection | 2 | 2019 | 40 | 0.180 |
Why?
|
| Neoadjuvant Therapy | 2 | 2018 | 5 | 0.180 |
Why?
|
| Survival Rate | 5 | 2019 | 111 | 0.170 |
Why?
|
| Child, Preschool | 3 | 2011 | 258 | 0.170 |
Why?
|
| Prostate-Specific Antigen | 2 | 2020 | 10 | 0.170 |
Why?
|
| Adenoma, Oxyphilic | 1 | 2020 | 1 | 0.170 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2020 | 2 | 0.170 |
Why?
|
| Preoperative Period | 1 | 2020 | 6 | 0.170 |
Why?
|
| Biomarkers, Tumor | 1 | 2020 | 51 | 0.160 |
Why?
|
| Prognosis | 4 | 2024 | 220 | 0.150 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2019 | 1 | 0.150 |
Why?
|
| RNA, Small Nuclear | 1 | 2019 | 1 | 0.150 |
Why?
|
| Thrombosis | 1 | 2019 | 13 | 0.150 |
Why?
|
| Nephroureterectomy | 1 | 2018 | 1 | 0.150 |
Why?
|
| Ureteral Neoplasms | 1 | 2018 | 1 | 0.150 |
Why?
|
| Ureteroscopy | 1 | 2018 | 1 | 0.150 |
Why?
|
| Hospitals | 1 | 2018 | 17 | 0.150 |
Why?
|
| Gastrointestinal Agents | 1 | 2018 | 6 | 0.140 |
Why?
|
| Drug Utilization | 1 | 2018 | 8 | 0.140 |
Why?
|
| Piperidines | 1 | 2018 | 7 | 0.140 |
Why?
|
| RNA, Long Noncoding | 1 | 2019 | 20 | 0.140 |
Why?
|
| RNA, Messenger | 1 | 2019 | 190 | 0.140 |
Why?
|
| Neoplasm, Residual | 1 | 2018 | 2 | 0.140 |
Why?
|
| Facial Nerve | 2 | 2008 | 2 | 0.140 |
Why?
|
| Facial Paralysis | 2 | 2008 | 2 | 0.140 |
Why?
|
| Urinary Diversion | 1 | 2018 | 1 | 0.140 |
Why?
|
| Time Factors | 2 | 2016 | 321 | 0.140 |
Why?
|
| Follow-Up Studies | 3 | 2018 | 268 | 0.140 |
Why?
|
| Preoperative Care | 1 | 2016 | 8 | 0.130 |
Why?
|
| Neoplasm Invasiveness | 1 | 2016 | 13 | 0.130 |
Why?
|
| Kidney Transplantation | 1 | 2018 | 101 | 0.130 |
Why?
|
| Nebraska | 1 | 2016 | 2 | 0.130 |
Why?
|
| Statistics as Topic | 1 | 2016 | 16 | 0.130 |
Why?
|
| Sensitivity and Specificity | 1 | 2016 | 98 | 0.120 |
Why?
|
| Cross-Sectional Studies | 2 | 2020 | 506 | 0.110 |
Why?
|
| Surgical Flaps | 2 | 2011 | 7 | 0.100 |
Why?
|
| Surgical Stapling | 1 | 2011 | 2 | 0.090 |
Why?
|
| Surgical Wound Infection | 1 | 2011 | 7 | 0.090 |
Why?
|
| Appendectomy | 1 | 2011 | 13 | 0.090 |
Why?
|
| Disease-Free Survival | 2 | 2024 | 24 | 0.090 |
Why?
|
| Oroantral Fistula | 1 | 2011 | 1 | 0.090 |
Why?
|
| Palate | 1 | 2011 | 1 | 0.090 |
Why?
|
| Infant | 1 | 2011 | 187 | 0.080 |
Why?
|
| Comorbidity | 1 | 2011 | 147 | 0.080 |
Why?
|
| Length of Stay | 1 | 2011 | 53 | 0.080 |
Why?
|
| Infant, Newborn | 1 | 2011 | 199 | 0.080 |
Why?
|
| Child | 2 | 2011 | 524 | 0.080 |
Why?
|
| Prevalence | 1 | 2011 | 259 | 0.080 |
Why?
|
| Adolescent | 5 | 2011 | 869 | 0.080 |
Why?
|
| Acrylic Resins | 1 | 2009 | 1 | 0.080 |
Why?
|
| Cosmetic Techniques | 1 | 2009 | 4 | 0.080 |
Why?
|
| Tumor Microenvironment | 2 | 2020 | 25 | 0.080 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2020 | 13 | 0.080 |
Why?
|
| Antineoplastic Agents, Immunological | 2 | 2020 | 8 | 0.080 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2020 | 21 | 0.070 |
Why?
|
| Radial Neuropathy | 1 | 2009 | 1 | 0.070 |
Why?
|
| Radial Nerve | 1 | 2009 | 2 | 0.070 |
Why?
|
| Bone Wires | 1 | 2009 | 2 | 0.070 |
Why?
|
| Humeral Fractures | 1 | 2009 | 2 | 0.070 |
Why?
|
| Fracture Fixation | 1 | 2009 | 2 | 0.070 |
Why?
|
| Arthrodesis | 1 | 2008 | 1 | 0.070 |
Why?
|
| Finger Joint | 1 | 2008 | 1 | 0.070 |
Why?
|
| Pemphigus | 1 | 2008 | 1 | 0.070 |
Why?
|
| Nail Diseases | 1 | 2008 | 3 | 0.070 |
Why?
|
| Risk Factors | 1 | 2011 | 767 | 0.070 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2018 | 23 | 0.070 |
Why?
|
| Multivariate Analysis | 2 | 2018 | 104 | 0.070 |
Why?
|
| Odds Ratio | 2 | 2018 | 82 | 0.070 |
Why?
|
| Databases, Factual | 2 | 2018 | 81 | 0.070 |
Why?
|
| Facial Asymmetry | 1 | 2007 | 1 | 0.070 |
Why?
|
| Peripheral Nerves | 1 | 2007 | 3 | 0.070 |
Why?
|
| Logistic Models | 2 | 2018 | 165 | 0.070 |
Why?
|
| Cohort Studies | 2 | 2018 | 285 | 0.060 |
Why?
|
| Prospective Studies | 2 | 2020 | 331 | 0.060 |
Why?
|
| Chromosomes | 1 | 2024 | 4 | 0.050 |
Why?
|
| Young Adult | 3 | 2011 | 567 | 0.050 |
Why?
|
| Treatment Outcome | 3 | 2011 | 500 | 0.050 |
Why?
|
| Proteomics | 1 | 2022 | 9 | 0.050 |
Why?
|
| Gallium Radioisotopes | 1 | 2020 | 1 | 0.040 |
Why?
|
| Gene Expression | 1 | 2020 | 77 | 0.040 |
Why?
|
| Diagnosis, Differential | 1 | 2020 | 79 | 0.040 |
Why?
|
| Computational Biology | 1 | 2020 | 13 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2020 | 18 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2020 | 54 | 0.040 |
Why?
|
| Patient Satisfaction | 2 | 2011 | 31 | 0.040 |
Why?
|
| Ultrasound, High-Intensity Focused, Transrectal | 1 | 2019 | 1 | 0.040 |
Why?
|
| Image-Guided Biopsy | 1 | 2019 | 3 | 0.040 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2020 | 88 | 0.040 |
Why?
|
| Neoplasm Metastasis | 1 | 2019 | 22 | 0.040 |
Why?
|
| Gene Dosage | 1 | 2019 | 2 | 0.040 |
Why?
|
| Genome | 1 | 2019 | 7 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2020 | 197 | 0.040 |
Why?
|
| False Negative Reactions | 1 | 2018 | 8 | 0.040 |
Why?
|
| Gene Expression Profiling | 1 | 2019 | 44 | 0.040 |
Why?
|
| Postoperative Care | 1 | 2018 | 8 | 0.040 |
Why?
|
| Lymph Node Excision | 1 | 2018 | 7 | 0.040 |
Why?
|
| Operative Time | 1 | 2018 | 8 | 0.040 |
Why?
|
| Transcriptome | 1 | 2019 | 31 | 0.040 |
Why?
|
| Biopsy | 1 | 2018 | 36 | 0.040 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2018 | 15 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2018 | 42 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 1 | 2018 | 84 | 0.030 |
Why?
|
| Kidney | 1 | 2020 | 184 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2018 | 108 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2018 | 169 | 0.030 |
Why?
|
| Age Factors | 1 | 2018 | 193 | 0.030 |
Why?
|
| Sex Factors | 1 | 2018 | 155 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2011 | 13 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2011 | 22 | 0.020 |
Why?
|
| Cleft Palate | 1 | 2011 | 1 | 0.020 |
Why?
|
| Edema | 1 | 2011 | 6 | 0.020 |
Why?
|
| Epithelium | 1 | 2011 | 22 | 0.020 |
Why?
|
| Appendicitis | 1 | 2011 | 15 | 0.020 |
Why?
|
| Wound Healing | 1 | 2011 | 14 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2011 | 73 | 0.020 |
Why?
|
| Buttocks | 1 | 2009 | 1 | 0.020 |
Why?
|
| Breast Implants | 1 | 2009 | 1 | 0.020 |
Why?
|
| Gels | 1 | 2009 | 5 | 0.020 |
Why?
|
| Face | 1 | 2009 | 4 | 0.020 |
Why?
|
| Biocompatible Materials | 1 | 2009 | 7 | 0.020 |
Why?
|
| Leg | 1 | 2009 | 5 | 0.020 |
Why?
|
| Lacerations | 1 | 2009 | 5 | 0.020 |
Why?
|
| Nails | 1 | 2008 | 1 | 0.020 |
Why?
|
| Pemphigoid, Benign Mucous Membrane | 1 | 2008 | 1 | 0.020 |
Why?
|
| Skin | 1 | 2008 | 10 | 0.020 |
Why?
|
| Sural Nerve | 1 | 2008 | 1 | 0.020 |
Why?
|
| Bell Palsy | 1 | 2008 | 1 | 0.020 |
Why?
|
| Anastomosis, Surgical | 1 | 2008 | 3 | 0.020 |
Why?
|
| Cicatrix | 1 | 2008 | 4 | 0.020 |
Why?
|
| Neurosurgical Procedures | 1 | 2007 | 6 | 0.020 |
Why?
|